scholarly journals RP215-based Anti-Cancer Drugs

2020 ◽  
Vol 1 (1) ◽  
Keyword(s):  
Cancer Cells ◽  
Cancer Immunotherapy ◽  
Serum Levels ◽  
Cancer Drugs ◽  
Variable Regions ◽  
Functional Roles ◽  
Heavy Chains ◽  
Anti Cancer ◽  
Car T ◽  
New Generation

Parallel to the conventional immunology, immunoglobulins can also be produced by many cancer cells of epithelial origins for unidentified functional roles. RP215 was the first monoclonal antibody generated in 1987 and shown to react with a carbohydrate-associated epitope located mainly in the variable regions of heavy chains of immunoglobulins expressed by cancer cells (designated as CA215), but not in those of B cell origin. Through years of biological and immunological studies, it has become apparent that dual differential roles are played by cancerous immunoglobulins. Therefore, cancerous immunoglobulins are essential for the growth and protection of cancer cells under our body environment. RP215 was found to be a unique probe for CA215 in the immunoassays to monitor serum levels of shed cancerous immunoglobulins among cancer patients for immunodiagnostic applications. Upon binding with surface expressed immunoglobulins, RP215 was shown to induce apoptosis and complementdependent cytotoxicity to many cancer cells. Humanized forms of RP215 can be used to target cancer cells of different tissue origins and are being developed into antibody-based anti-cancer drugs for cancer immunotherapy. A new generation of chimeric antigen (CAR)-T cell technology is being utilized to introduce humanized RP215 gene transfected to T cells for cancer immunotherapy of selected sets of human cancers.

scholarly journals Surface polymer imprinted optical fibre sensor for dose detection of dabrafenib

The Analyst ◽  
2020 ◽  
Vol 145 (13) ◽  
pp. 4504-4511 ◽  
Author(s):  
Chenyang He ◽  
Ulises Hernandez Ledezma ◽  
Pratik Gurnani ◽  
Thais Albelha ◽  
Kristofer J. Thurecht ◽  
...  
Keyword(s):  
Optical Fibre ◽  
Cancer Drugs ◽  
Optical Fibre Sensor ◽  
Anti Cancer ◽  
Fibre Sensor ◽  
New Generation

Dabrafenib is one of the most widely used of the new generation of targeted anti-cancer drugs.

scholarly journals Intracellular delivery of NF-κB small interfering RNA for modulating therapeutic activities of classical anti-cancer drugs in human cervical cancer cells

2013 ◽  
Vol 3 (1) ◽  
pp. 7 ◽  
Author(s):  
Anthony Stanislaus ◽  
Anil Philip Kunnath ◽  
Snigdha Tiash ◽  
Tahereh Fatemian ◽  
Nur Izyani Kamaruzman ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Cells ◽  
Intracellular Delivery ◽  
Cyclin B1 ◽  
Carbonate Apatite ◽  
Cancer Drugs ◽  
Small Interfering Rnas ◽  
Strong Electrostatic Interaction ◽  
Anti Cancer ◽  
Gene Transcripts

Cervical cancer is the second most common cancer and fourth leading cause of cancer-related deaths among women. Advanced stage of the disease is treated with radiation therapy and chemotherapy with poor therapeutic outcome and adverse side effects. NFκB, a well-known transcription factor in the control of immunity and inflammation, has recently emerged as a key regulator of cell survival through induction of antiapoptotic genes. Many human cancers, including cervical carcinoma, constitutively express NF-κB and a blockade in expression of its subunit proteins through targeted knockdown of the gene transcripts with small interfering RNAs (siRNA) could be an attractive approach in order to sensitize the cancer cells towards the widely used anti-cancer drugs. However, the inefficiency of the naked siRNA to cross the plasma membrane and its sensitiveness to nuclease-mediated degradation are the major challenges limiting the siRNA technology in therapeutic intervention. pH-sensitive carbonate apatite has been established as an efficient nano-carrier for intracellular delivery of siRNA, due to its strong electrostatic interaction with the siRNA, the desirable size distribution of the resulting siRNA complex for effective endocytosis and the ability of the endocytosed siRNA to be released from the degradable particles and escape the endosomes, thus leading to the effective knockdown of the target gene of cyclin B1 or ABCB1. Here, we report that carbonate apatite-facilitated delivery of the siRNA targeting NF-κB1 and NF-κB2 gene transcripts in HeLa, a human cervical adenocar- cinoma cell line expressing NF-κB, led to a synergistic effect in enhancement of chemosensitivity to doxorubicin, but apparently not to cisplatin or paclitaxel.

Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells

APOPTOSIS ◽  
2006 ◽  
Vol 11 (7) ◽  
pp. 1205-1214 ◽  
Author(s):  
K. O'Connor ◽  
C. Gill ◽  
M. Tacke ◽  
F.-J. K. Rehmann ◽  
K. Strohfeldt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Cancer Drugs ◽  
Prostate Cancer Cells ◽  
Apoptotic Pathway ◽  
Anti Cancer

scholarly journals Synthetic sphingolipid analogs and anti-cancer drugs synergistically induced human colon and pancreatic cancer cell death through inhibiting ceramide metabolism

2021 ◽  
Author(s):  
Jing Song ◽  
Arie Dagan
Keyword(s):  
Pancreatic Cancer ◽  
Cell Death ◽  
Cancer Cells ◽  
Human Cancer ◽  
Human Colon ◽  
Cancer Drugs ◽  
Human Cancer Cells ◽  
Low Concentrations ◽  
Anti Cancer ◽  
Sphingolipid Analogs

AbstractCeramide metabolism is a potential target for anti-cancer therapy. Studies show that chemotherapeutic agents can induce apoptosis and it is mediated by ceramide. Synthesized sphingolipid analogs can induce cell death in human lymphocytes and leukemia cells. By screening a group of synthetic sphingolipid analogs, we found that low concentrations of AD2750 and AD2646 induced cell death in human cancer cells by preventing ceramide from converting to sphingomyelin, individually or in combination with commercial cancer drugs. The combination of low concentrations of Taxol and AD2750 or AD2646 significantly increased cell death on human colon cancer cells (HT29). Co-administering low concentrations of Doxorubicin with AD2750 or AD2646 elevated cellular toxicity on human pancreatic cancer cells (CRL1687). This synergistic effect is related to the elevated cellular ceramide. Combining AD2750 or AD2646 with chemotherapy drugs can be used to manipulate ceramide and sphingomyelin metabolism, potentially to affect the growth of human cancer cells and increase the effectiveness of anti-cancer drugs on killing cancer cells.

scholarly journals Overcoming the problem of the lack of an immune response to cancer: A possible haptogenic approach to cancer immunotherapy

2021 ◽  
Vol 5 (1) ◽  
pp. 01-04
Author(s):  
Patrick Riley
Keyword(s):  
Immune Response ◽  
Cancer Cells ◽  
Cancer Immunotherapy ◽  
Immunological Response ◽  
Gene Products ◽  
Malignant Cells ◽  
Deviant Behaviour ◽  
Anti Cancer ◽  
Immune Response To Cancer ◽  
Normal Gene

Cancer cells possess a number of unusual features, most of which are explicable in the light of the theory of epigenetic carcinogenesis. This includes the remarkable failure of malignant cells to evoke an immunological response from the host which is ascribed to their deviant behaviour resulting from anomalous expression of normal gene products. Given this background a possible approach to eliciting a specific anti-cancer immune response is proposed which involves selective haptenation of an identifiable target protein.

scholarly journals How Can Dogs and Cats Help to Cure Human Cancers?

2022 ◽  
Vol 9 ◽  
Author(s):  
Laura Bongiovanni ◽  
Philip J. Bergman ◽  
Alain de Bruin
Keyword(s):  
Cancer Cells ◽  
Medical Doctors ◽  
Cancer Drugs ◽  
Pet Dogs ◽  
New Therapies ◽  
Best Friends ◽  
Human Cancers ◽  
Anti Cancer ◽  
Working Together ◽  
Speed Up

Like their owners, dogs and cats can be affected by several types of cancer, and some types are very similar to those seen in people. Unfortunately, there is still no cure for several types of cancer. How can humans’ best friends help? If a new therapy to fight cancer works well in pets, it is likely to also be effective in people with the same type of cancer. Scientists, medical doctors, and animal doctors are working together to develop new therapies that destroy cancer cells and save patients. Since the characteristics of certain types of cancer are very similar between humans and pets, new medicines that work in pet dogs or cats may also benefit human patients. Studying these “human-like” cancers in pets may speed up the development of effective anti-cancer drugs and will help to cure not only more dogs and cats, but also people with cancer.

Sign in / Sign up

Export Citation Format

Share Document